Osimertinib is more frequently used as a 2nd-line treatment for NSCLC patients with secondary T790M mutations after 1st- and 2nd-generation EGFR-TKIs than as a first-line treatment [37, 38]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.